Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelines

[1]  Y. Imai,et al.  Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case–control study , 2011, Journal of Gastroenterology.

[2]  T. Arakawa,et al.  Incidence of hepatocellular carcinoma in hepatitis C carriers with normal alanine aminotransferase levels. , 2009, Journal of hepatology.

[3]  M. Ghany,et al.  Diagnosis, management, and treatment of hepatitis C: An update , 2009, Hepatology.

[4]  Edward A Belongia,et al.  National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. , 2009, Annals of internal medicine.

[5]  R. Guarisco,et al.  Antiviral treatment of HCV carriers with persistently normal ALT levels. , 2008, Mini reviews in medicinal chemistry.

[6]  E. Bini,et al.  Sustained virological response rates and health‐related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels , 2006, Alimentary pharmacology & therapeutics.

[7]  Sanjeev Arora,et al.  Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon α‐2a (40 kDa) plus ribavirin: Impact on health‐related quality of life , 2006, Journal of gastroenterology and hepatology.

[8]  Sanjeev Arora,et al.  Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life. , 2006, Journal of gastroenterology and hepatology.

[9]  T. Nakajima,et al.  A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. , 2005, Journal of hepatology.

[10]  R. Guarisco,et al.  Chronic hepatitis C and 'normal' ALT levels: treat the disease not the test. , 2005, Journal of hepatology.

[11]  K. Reddy,et al.  Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. , 2004, Gastroenterology.

[12]  E. Keeffe,et al.  Chronic hepatitis C with normal aminotransferase levels. , 2004, Gastroenterology.

[13]  P. Marcellin,et al.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.

[14]  A. Mangia,et al.  Clinical management of HCV carriers with normal aminotransferase levels. , 2003, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[15]  J. Hoofnagle,et al.  National institutes of health consensus development conference statement: Management of hepatitis C: 2002 — June 10–12, 2002 , 2002, HIV clinical trials.

[16]  T. Asselah,et al.  Fibrosis and disease progression in hepatitis C , 2002, Hepatology.

[17]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[18]  A. Zanella,et al.  Updated Definitions of Healthy Ranges for Serum Alanine Aminotransferase Levels , 2002, Annals of Internal Medicine.

[19]  P. Marcellin,et al.  Predictive value of ALT levels for histologic findings in chronic hepatitis C: A European collaborative study , 2002, Hepatology.

[20]  P. Marcellin,et al.  Prospective study on anti‐hepatitis C virus–positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA , 2001, Hepatology.

[21]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[22]  S. Shirahama,et al.  Risk of alanine aminotransferase flare‐up among asymptomatic hepatitis C virus RNA carriers: A 10‐year follow‐up study , 2001, Journal of gastroenterology and hepatology.

[23]  P. Marcellin,et al.  Predictive value of alt levels on histological findings in chronic hepatitis C: a European collaborative study , 2001 .

[24]  F. Montagnese,et al.  Hepatitis C virus carriers with persistently normal aminotransferase levels: healthy people or true patients? , 2000, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[25]  J. Raufman,et al.  Liver biopsy in the evaluation of patients with chronic hepatitis C who have repeatedly normal or near-normal serum alanine aminotransferase levels. , 2000, The American journal of medicine.

[26]  M. Tong,et al.  The long‐term outcomes of patients with compensated hepatitis C virus–related cirrhosis and history of parenteral exposure in the united states , 1999, Hepatology.

[27]  N. Tassopoulos.  Treatment of patients with chronic hepatitis C and normal ALT levels. , 1999, Journal of hepatology.

[28]  P. Marcellin,et al.  Hepatitis C: the clinical spectrum of the disease. , 1999, Journal of hepatology.

[29]  O. Chazouilleres,et al.  Determinants of outcome of compensated hepatitis C virus‐related cirrhosis , 1998, Hepatology.

[30]  R. Ceriani,et al.  Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: A pilot randomized controlled study , 1998, Hepatology.

[31]  A. Magrini,et al.  Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels , 1997, Hepatology.

[32]  A. Bhalla,et al.  Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. , 1997, Gastroenterology.

[33]  P. Bedossa,et al.  An algorithm for the grading of activity in chronic hepatitis C , 1996, Hepatology.

[34]  Richard L. Abbott,et al.  A Follow-up Study , 1990 .

[35]  Harold C. Sox,et al.  National Institutes of Health Consensus Development Conference Statement: Geriatric Assessment Methods for Clinical Decision‐making , 1988 .

[36]  C. Paúl,et al.  Education, leisure activities and cognitive and functional ability of Alzheimer's disease patients: A follow-up study , 2013, Dementia & neuropsychologia.